Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Total Debt
Short-term and long-term borrowings combined.
Monopar Therapeutics Inc.NASDAQ: MNPR
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt remains negative
Q1 FY2026 total debt was $131.57K, compared with $0 a year earlier. Over 3 fiscal years it compounded at +164.1% a year.
Context
- Total debt amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 154.92K USD
- Year-over-year change
- —
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 154.92K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 8.41K | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Debt vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Total debt amounts to 0.1% of total assets for MNPR, versus a peer median of 6.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $662.71M USD | +3405.7% | -13.4% | 56.3% | |
| Mar 2026 | $116.67M USD | -74.1% | +50.1% | 40.0% | |
| Jun 2026 | $65.21M USD | -4.0% | +46.6% | 9.0% | |
| Mar 2026 | $36.51M USD | -2.6% | +45.3% | 16.8% | |
| Dec 2025 | €22.56M EUR | -27.2% | -18.9% | 36.0% | |
| Mar 2026 | $15.34M USD | +68.2% | -26.6% | 2.4% | |
| Sep 2026 | $10.26M USD | +155.6% | +136.6% | 2.0% | |
| Mar 2026 | $9.79M USD | +53.4% | +49.6% | 4.8% | |
| Mar 2026 | $5.22M USD | -47.7% | -20.6% | 2.9% | |
| Jun 2026 | $1.34M USD | +4.0% | -13.1% | 3.3% | |
| Mar 2026 | $131.57K USD | — | +164.1% | 0.1% | |
| Peer median (excluding MNPR) | — | +0.7% | +16.1% | 6.9% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.